WHO Advances Malaria Treatment and Diagnostics for Vulnerable Populations
The World Health Organization has announced two significant public-health developments in malaria management ahead of World Malaria Day 2026.
New Infant Malaria Treatment
WHO prequalified artemether-lumefantrine as the first antimalarial formulation specifically designed for newborns and young infants weighing 2–5 kilograms. This addresses a critical treatment gap affecting approximately 30 million babies born annually in malaria-endemic regions of Africa.
Previously, infants received formulations intended for older children, creating substantial risks of dosing errors, adverse effects, and toxicity. The WHO prequalification designation confirms the medicine meets international standards for quality, safety, and efficacy, enabling public-sector procurement and expanding access to appropriate pediatric treatment.
Addressing Diagnostic Resistance
WHO simultaneously prequalified three new rapid diagnostic tests (RDTs) targeting emerging diagnostic challenges. Conventional HRP2-based tests detect a parasite protein that some Plasmodium falciparum strains have evolved to eliminate through gene deletion. In Horn of Africa regions, up to 80% of cases were missed by standard RDTs, resulting in delayed treatment and severe outcomes.
The new tests utilize alternative parasite protein detection (pf-LDH), which parasites cannot easily eliminate. WHO recommends countries switch to these alternative RDTs when HRP2-based tests miss more than 5% of cases, ensuring accurate diagnosis and appropriate treatment initiation.
Current Global Context
The 2025 World Malaria Report documented 282 million cases and 610,000 deaths in 2024—an increase from 2023. While 47 countries achieved malaria-free status and 37 reported fewer than 1,000 cases, global progress remains challenged by drug resistance, insecticide resistance, diagnostic failures, and reduced development assistance.
Positive developments include 25 countries rolling out malaria vaccines and next-generation mosquito nets comprising 84% of new distributions. Since 2000, interventions have prevented 2.3 billion infections and saved 14 million lives.
Pharmacist's Note: Travelers to malaria-endemic areas should consult healthcare providers about appropriate chemoprophylaxis based on travel destination, duration, and individual risk factors. The new infant treatment represents important progress for pediatric populations; however, prevention through mosquito avoidance and prophylaxis remains the primary strategy for travelers. Diagnostic advances improve case identification in resource-limited settings, supporting timely treatment initiation when infection occurs.